Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapy
Pepijn W. A. Thomas(Radboud University Nijmegen), Frank Hoentjen(Radboud University Nijmegen), Naomi T. Jessurun(Netherlands Pharmacovigilance Centre Lareb), Jette A. van Lint(Netherlands Pharmacovigilance Centre Lareb), Tessa E H Römkens(Jeroen Bosch Ziekenhuis), Rachel West(Sint Franciscus Gasthuis), Jeroen M. Jansen(OLVG), Maurice G. Rüssel(Medisch Spectrum Twente)
Cited by 16
Related Papers
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis
|New England Journal of Medicine|2021|269
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252
Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis
|Gastroenterology|2020|233
Reduction of Colitis by Prebiotics in HLA-B27 Transgenic Rats Is Associated with Microflora Changes and Immunomodulation
|Inflammatory Bowel Diseases|2005|215